Abstract
:
The heterogeneous and complex nature of cancer is extensively revealed at molecular,
genetic, and tissue microenvironment levels. Currently, co-occurrence of coronavirus disease 2019
(COVID-19) to lung cancer patients and severity of infections by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been understood at preclinical and clinical levels. However,
molecular and cellular insights are not discussed in those papers that support the increased
COVID-19 severity and comorbidities in several cancer types, including lung cancer patients.
Therefore, this perspective highlights the basis of high severity and comorbidities among lung cancer
patients infected by COVID-19 with an emphasis on translational aspects.